Cargando…

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy

Detalles Bibliográficos
Autores principales:	Ucciferri, Claudio, Falasca, Katia, Vignale, Francesca, Di Nicola, Marta, Vecchiet, Jacopo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427639/ https://www.ncbi.nlm.nih.gov/pubmed/26971833 http://dx.doi.org/10.1016/j.bjid.2016.02.002

Ejemplares similares

Long term effect of telmisartan in HIV-positive male patients with high blood pressure
por: Ucciferri, Claudio, et al.
Publicado: (2015)

Cystatin C and cardiovascular risk in HIV infected patients
por: Falasca, Katia, et al.
Publicado: (2010)

Hypertension and microalbuminuria in HIV infected patients: beneficial effects of the treatment with telmisartan
por: Ucciferri, Claudio, et al.
Publicado: (2010)

The impact of homocysteine, B(12), and D vitamins levels on functional neurocognitive performance in HIV-positive subjects
por: Falasca, Katia, et al.
Publicado: (2019)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Role of monoclonal antibody drugs in the treatment of COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study
por: Falasca, Katia, et al.
Publicado: (2015)

Cardiac Toxicity Associated with HCV Direct Antiviral Agents
por: Ucciferri, Claudio, et al.
Publicado: (2018)

Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
por: Falasca, Katia, et al.
Publicado: (2017)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Use of Hematopoietic Growth Factor in the Management of Hematological Side Effects Associated to Antiviral Treatment for Hcv Hepatitis
por: Mancino, Paola, et al.
Publicado: (2010)

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
por: Ucciferri, Claudio, et al.
Publicado: (2023)

New Therapeutic Options in Mild Moderate COVID-19 Outpatients
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Parameters associated with diagnosis of COVID‐19 in emergency department
por: Ucciferri, Claudio, et al.
Publicado: (2021)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
por: Mishra, Tulsidas, et al.
Publicado: (2014)

Risk Factors Associated with Poor Outcome in Patients with Infective Endocarditis: An Italian Single-Center Experience
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV
por: Reale, Marcella, et al.
Publicado: (2021)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
por: Katia, Falasca, et al.
Publicado: (2021)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms
por: Gao, Xiaobo, et al.
Publicado: (2019)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qa1v26jq8k2ncujcjvm42lrh5u